Tadalafil: a clinical update

Abstract

Oral phosphodiesterase type-5 inhibitors are the contemporary choice for first-line treatment of erectile dysfunction in most men. Due to its efficacy, safety and ease-of-use, tadalafil is preferred by many men suffering from erectile dysfunction of varying severity and etiology. In this review, pharmacodynamic and updated clinical data from integrated analyses and postmarketing surveillance of tadalafil are reported, including efficacy results for specific patient subpopulations, treatment guidelines and compiled safety data including a review of nonarteritic anterior ischemic optic neuropathy and possible links to the use of phosphodiesterase-5 inhibitors.